AI meets biology: How cellular intelligence is redefining stem cell therapy

Cells have always been the body's original intelligence system, sensing, adapting, and repairing with remarkable precision. Now, artificial intelligence is beginning to mirror this biological brilliance, fundamentally changing how diseases are diagnosed and treated.

Stem-cell therapy, once a slow process of laboratory work and trial-and-error, is being reshaped by AI-native platforms. These platforms are transforming how scientists design, test, and manufacture living medicines. Cellular Intelligence, a Boston-based company co-founded by Israeli entrepreneur Dr. Micha Breakstone, is at the forefront of this shift. The company aims to revolutionize stem cell research and create innovative solutions for devastating diseases.

Breakstone, who previously co-founded the Israeli tech company Chorus.ai, has positioned Cellular Intelligence at the nexus of computational modeling and regenerative medicine. The company's scientific foundation was built in collaboration with researchers from Harvard Medical School and other institutions. Their platform integrates advanced cellular data methods with a foundation model trained on extensive cellular perturbation conditions. This system is designed to incorporate data from clinical and manufacturing processes, creating a feedback loop that enhances predictive accuracy over time.

The ultimate goal is to facilitate the development of cell therapies that can be produced reliably and at scale, overcoming a major hurdle that has previously limited the field. Cellular Intelligence states that by merging large-scale cellular data with AI, they are

“

We are using AI to understand how cells communicate and to make new tissue.